{"id":"azd9833-with-anastrozole","safety":{"commonSideEffects":[{"rate":"null","effect":"Hot flashes"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1399","moleculeType":"Small molecule","molecularWeight":"293.37"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD9833 is a selective estrogen receptor degrader (SERD) that inhibits estrogen receptor alpha (ERα) signaling, which is involved in the growth and survival of hormone receptor-positive breast cancer cells.","oneSentence":"Estrogen receptor inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:39:18.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer"}]},"trialDetails":[{"nctId":"NCT06380751","phase":"PHASE3","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-01","conditions":"Advanced Breast Cancer","enrollment":500},{"nctId":"NCT05774951","phase":"PHASE3","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-31","conditions":"Breast Cancer, Early Breast Cancer","enrollment":4300},{"nctId":"NCT03616587","phase":"PHASE1","title":"Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-10-11","conditions":"ER+ HER2- Advanced Breast Cancer","enrollment":396},{"nctId":"NCT04964934","phase":"PHASE3","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-30","conditions":"ER-Positive HER2-Negative Breast Cancer","enrollment":315},{"nctId":"NCT04711252","phase":"PHASE3","title":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-01-28","conditions":"ER-Positive HER2-Negative Breast Cancer","enrollment":1370},{"nctId":"NCT05952557","phase":"PHASE3","title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-10-05","conditions":"Breast Cancer, Early Breast Cancer","enrollment":5500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AZD9833 with anastrozole","genericName":"AZD9833 with anastrozole","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Estrogen receptor inhibitor Used for Hormone receptor-positive breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}